Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis

Cochrane Database of Systematic Reviews

Volumn 2019, Issue 5, 2019, Pages

  Nguyen, Nghia ^a   Zhang, Bing ^b   Holubar, Stefan D ^c   Pardi, Darrell S ^d   Singh, Siddharth ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALLOPURINOL; BISMUTH CITRATE; BUDESONIDE; BUTYRIC ACID; CIPROFLOXACIN; ENEMA; GLUTAMINE; LIVER ENZYME; METRONIDAZOLE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; TINIDAZOLE; VSL3; ANTIINFECTIVE AGENT; GASTROINTESTINAL AGENT; BISMUTH;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ALLERGIC REACTION; ANOREXIA; ASTHENIA; BIFIDOBACTERIUM LONGUM; CANDIDIASIS; CHEMOPROPHYLAXIS; CLOSTRIDIUM; CLUSTER HEADACHE; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSGEUSIA; EVENING DOSAGE; FLATULENCE; GYNECOMASTIA; HEADACHE; HUMAN; ILEAL POUCH-ANAL ANASTOMOSIS; ILEITIS; LACTOBACILLUS; LIVER DYSFUNCTION; MALAISE; METALLIC TASTE; MUSCLE CRAMP; NAUSEA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIMARY PREVENTION; PRIORITY JOURNAL; PROCTALGIA; PRURITUS; REMISSION; REVIEW; SIDE EFFECT; SINUSITIS; SYSTEMATIC REVIEW; THIRST; TREATMENT OUTCOME; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANASTOMOSIS; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE OUTCOME; ARTICLE; CLINICAL EFFECTIVENESS; HYPERTRANSAMINASEMIA; OUTCOME ASSESSMENT; POLYDIPSIA; ADVERSE EVENT; META ANALYSIS;

ANASTOMOSIS, SURGICAL; ANTI-BACTERIAL AGENTS; BUDESONIDE; CIPROFLOXACIN; COLITIS, ULCERATIVE; ENEMA; GASTROINTESTINAL AGENTS; HUMANS; METRONIDAZOLE; POSTOPERATIVE COMPLICATIONS; POUCHITIS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 85066939041     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001176.pub4     Document Type: Review

References (72)

1. Brown SJ, Megan J, Smith S, Matchet D, Elliott R. Bifidobacterium longum BB-536 and prevention of acute pouchitis. Gastroenterology 2004;126(4 Suppl 2):S465.
2. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119 (2):305–9.
3. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lammers KM, Brigidi P, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124(5):1202–9.
4. Ha CY, Bauer JJ, Lazarev M, Swaminath A, Sparrow M, Murphy SJ, et al. Early institution of tinidazole may prevent pouchitis following ileal pouch-anal anastomosis (IPAA) surgery in ulcerative colitis (UC) patients. Gastroenterology 2010;138(5 Suppl 1):S69.
5. Isaacs KL, Sandler RS, Abreu M, Picco MF, Hanauer SB, Bickston SJ, et al. Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflammatory Bowel Diseases 2007;13(10): 1250–5.
6. Joelsson M, Andersson M, Bark T, Gullberg K, Hallgren T, Jiborn H, et al. Allopurinol as prophylaxis against pouchitis following ileal pouch-anal anastomosis for ulcerative colitis. A randomized placebo-controlled double-blind study. Scandinavian Journal of Gastroenterology 2001;36(11): 1179–84.
7. Kjaer MD, Qvist N, Nordgaard-Lassen I, Christensen LA, Kjeldsen J. Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial. Scandinavian Journal of Gastroenterology 2019;54(2): 188–93.
8. Kuisma J, Mentula S, Jarvinen H, Kahri A, Saxelin M, Farkkila M. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Alimentary Pharmacology and Therapeutics 2003;17(4):509–15.
9. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53(1):108–14.
10. Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflammatory Bowel Diseases 2008;14(5):662–8.
11. Sambuelli A, Boerr L, Negreira S, Gil A, Camartino G, Huernos S, et al. Budesonide enema in pouchitis-A double-blind, double-dummy, controlled trial. Alimentary Pharmacology and Therapeutics 2002;16(1):27–34.
12. Shen B, Achkar JP, Lashner BA, Ormsby A, Remzi F, Bevins CL, et al. Ciprofloxacin is more effective in treating acute pouchitis than metronidazole: A randomized clinical trial. Gastroenterology 2001;120(5 Suppl 1):A453.
13. Tremaine WJ, Sandborn WJ, Wolff BG, Carpenter HA, Zinsmeister AR, Metzger PP. Bismuth carbomer foam enemas for active chronic pouchitis: a randomized, double-blind, placebo-controlled trial. Alimentary Pharmacology and Therapeutics 1997;11(6):1041–6.
14. Wischmeyer P, Pemberton JH, Phillips SF. Chronic pouchitis after ileal pouch-anal anastomosis: responses to butyrate and glutamine suppositories in a pilot study. Mayo Clinic Proceedings 1993;68(10):978–81.
15. Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, et al. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis.. Surgery Today 2016;46(8):939–49. PUBMED: 26510664]
16. Bengtsson J, Adlerberth I, Östblom A, Saksena P, Öresland T, Börjesson L. Effect of probiotics (Lactobacillus plantarum 299 plus Bifidobacterium Cure21) in patients with poor ileal pouch function: a randomised controlled trial.. Scandinavian Journal of Gastroenterology 2016;51(9): 1087–92. PUBMED: 27150635 ]
17. Kuhbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006;55(6): 833–41.
18. Laake KO, Bjørneklett A, Aamodt G, Aabakken L, Jacobsen M, Bakka A, et al. Outcome of four weeks’ intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scandinavian Journal of Gastroenterology 2005;40(1):43–51.
19. Madden MV, McIntyre AS, Nicholls RJ. Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis. Digestive Diseases and Sciences 1994; 39(6):1193–6.
20. McLeod RS, Taylor DW, Cohen Z, Cullen JB. Single-patient randomised clinical trial. Use in determining optimum treatment for patients with inflammation of Kock continent ileostomy reservoir. Lancet 1986;1(8483):726–8.
21. Meijer HP, Welters CF, Heineman E, Salomons GS, Buller HA, Dekker J, et al. Enteral inulin doles not affect epithelial gene expression and cell turnover within the ileoanal pouch-Randomized, placebo-controlled, crossover study. Diseases of the Colon and Rectum 2000;43(10):1427–34.
22. Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: A randomized, double-blind, active-controlled trial. Alimentary Pharmacology and Therapeutics 2006;23(10):1403–13.
23. Tomasz B, Zoran S, Jaros aw W, Ryszard M, Marcin G, Robert B, et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study. Biomedical Research International 2014; NR:208064.
24. van Assche G, Ferrante M, Vermeire S, Noman M, Rans K, Van der Biest L, et al. Octreotide for the treatment of diarrhoea in patients with ileal pouch-anal anastomosis: a placebo-controlled crossover study. Colorectal Diseases 2012; 14(4):181–6.
25. van Deventer SJ, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Alimentary Pharmacology and Therapeutics 2006;23(10):1415–25.
26. Welters CF, Heineman E, Thunnissen FB, van den Bogaard AE, Soeters PB, Baeten CG. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Diseases of the Colon and Rectum 2002;45(5):621–7.
27. Boerr LA, Sambuelli AM, Sugai E, Graziano A, Valero J, Kogan Z, et al. Faecal alpha-1-antitrypsin concentration in the diagnosis and management of patients with pouchitis. European Journal of Gastroenterology and Hepatology 1995;7 (2):129–33.
28. Boerr LA, Sambuelli AM, Filinger E, Peredo A, Graziano A, Valero J, et al. Increased mucosal levels of leukotriene B4 in pouchitis: evidence for a persistent inflammatory state. European Journal of Gastroenterology and Hepatology 1996;8 (1):57–61.
29. Bonello JC, Thow GB, Manson RR. Mucosal enteritis: a complication of the continent ileostomy. Diseases of the Colon and Rectum 1981;24(1):37–41.
30. Bär F, Kühbacher T, Dietrich NA, Krause T, Stallmach A, Teich N, et al. Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.. Alimentary Pharmacology and Therapeutics 2018;47(5): 581–7. [PUBMED: 29266360]
31. Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice.. Inflammatory Bowel Diseases 2006;12(1): 29–32.
32. Clausen MR, Tvede M, Mortensen PB. Short-chain fatty acids in pouch contents with and without pouchitis after ileal pouch-anal anastomosis. Gastroenterology 1992;103(4): 1144–53.
33. De Silva HJ, Ireland A, Kettlewell M, Mortensen N, Jewell DP. Short-chain fatty acid irrigation in severe pouchitis. New England Journal of Medicine 1989;321(20):416–7.
34. den Hoed PT, van Goch JJ, Veen HF, Ouwendijk RJ. Severe pouchitis successfully treated with short-chain fatty acids. Canadian Journal of Surgery 1996;39(2):168–9.
35. Di Febo G, Miglioli M, Lauri A, Biasco G, Paganelli GM, Poggioli G, et al. Endoscopic assessment of acute inflammation of the reservoir after restorative ileoanal anastomosis. Gastrointestinal Endoscopy 1990;36(1):6–9.
36. Gionchetti P, Rizzello F, Venturi A, Ferretti M, Brignola C, Peruzzo S, et al. Long-term efficacy of bismuth carbomer enemas in patients with treatment-resistant chronic pouchitis. Alimentary Pharmacology and Therapeutics 1997; 11(4):673–8.
37. Gionchetti P, Rizzello F, Poggioli G, Pierangeli F, Laureti S, Morselli C, et al. Oral budesonide in the treatment of chronic refractory pouchitis. Alimentary Pharmacology and Therapeutics 2000;25(10):1231–6.
38. Gupta I, Parihar GA, Malhotra P, Singh GB, Ludtke R, Safayhi H, et al. Effects of Boswella serrata gum resin in patients with ulcerative colitis. European Journal of Medical Research 1997;2(1):37–43.
39. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336(7650):924–6.
40. Herfarth HH, Long MD, Isaacs KL. Use of Biologics in Pouchitis: A Systematic Review. Journal of Clinical Gastroenterology 2015;49(8):647–54.
41. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
42. Hurst RD, Molinari M, Chung TP, Rubin M, Michelassi F. Prospective study of incidence, timing, and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy. Archives of Surgery 1996;131(5):497–502.
43. Kelly DG, Phillips SF, Kelly KA, Weinstein WM, Gilchrist MJ. Dysfunction of the continent ileostomy: clinical features and bacteriology. Gut 1983;24(3):193–201.
44. Klein K, Stenzel P, Katon RM. Pouch ileitis: report of a case with severe systemic manifestations. Journal of Clinical Gastroenterology 1983;5(2):149–53.
45. Kmiot WA, Hesslewood SR, Smith N, Thompson H, Harding LK, Keighley MR. Evaluation of the inflammatory infiltrate in pouchitis with 111-In-labeled granulocytes. Gastroenterology 1993;104(4):981–8.
46. Knobler H, Ligumsky M, Okon E, Ayalon A, Nesher R, Rachmilewitz D. Pouch ileitis-recurrence of the inflammatory bowel disease in the ileal reservoir. American Journal of Gastroenterology 1986;81(3):199–201.
47. Levin KE, Pemberton JH, Phillips SE, Zinsmeister AR, Pezim ME. Role of oxygen free radicals in etiology of pouchitis. Diseases of the Colon and Rectum 1992;35(5): 452–6.
48. Lohmuller JL, Pemberton JH, Dozois RR, Ilstrup D, Van Heerden J. Pouchitis and extraintestinal manifestations of inflammatory bowel disease after ileal pouch-anal anastomosis. Annals of Surgery 1990;211(5):622–9.
49. Moskowitz RL, Shepherd NA, Nicholls RJ. An assessment of inflammation in the reservoir after restorative proctocolectomy with ileoanal ileal reservoir. International Journal of Colorectal Disease 1986;1(3):167–74.
50. Nasmyth DG, Godwin PG, Dixon MF, Williams NS, Johnston D. Ileal ecology after pouch-anal anastomosis or ileostomy. A study of mucosal morphology, fecal bacteriology, fecal volatile fatty acids, and their interrelationship. Gastroenterology 1989;96(3):817–24.
51. Natori H, Utsunomiya J, Yamamura T, Benno Y, Uchida K. Fecal and stomal bile acid composition after ileostomy or ileoanal anastomosis in patients with chronic ulcerative colitis and adenomatous coli. Gastroenterology 1992;102(4 Pt 1):1278–88.
52. Nikfar S, Darvish-Damavandi M, Abdollahi M. A review and meta-analysis of the efficacy of antibiotics and probiotics in management of pouchitis. International Journal of Pharmacology 2010;6(6):826–35.
53. Pardi DS, Sandborn WJ. Systematic review: the management of pouchitis. Alimentary Pharmacology and Therapeutics 2006;23(8):1087–96.
54. Pardi DS, D’Haens G, Shen B, Campbell S, Gionchetti P. Guidelines for the clinical management of pouchitis. Inflammatory Bowel Diseases 2009;15(9):1423–31.
55. Pullan RD, Ganesh S, Mani V, Morris J, Evans BK, Williams GT, et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial. Gut 1993;34(5):676–9.
56. Sandborn WJ. Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment. Gastroenterology 1994;107(6):1856–60.
57. Sandborn WJ, Tremiane WJ, Batts KP, Pemberton JH, Phillips SF. Pouchitis following ileal pouch-anal anastomosis: a pouchitis disease activity index. Mayo Clinic Proceedings 1994;69(5):409–15.
58. Sandborn WJ, Tremaine WJ, Batts KP, Pemberton JH, Rossi SS, Hofmann AF, et al. Fecal bile acids, short chain fatty acids, and bacteria after ileal pouch-anal anastomosis do not differ in patients with pouchitis. Digestive Diseases and Sciences 1995;40(7):1474–83.
59. Sandborn WJ. Pouchitis: definition, risk factors, frequency, natural history, classification, and public health perspectives. In: McLeod RS, Martin F, Sutherland LR, Wallace JL, Williams CN editor(s). Trends In Inflammatory Bowel Disease 1996. Lancaster, UK: Kluwer Academic Publishers, 1997:51–63.
60. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
61. Scott AD, Phillips RK. Ileitis and pouchitis after colectomy for ulcerative colitis. British Journal of Surgery 1989;76(7): 668–9.
62. Segal JP, Ding NS, Worley G, Mclaughlin S, Preston S, Faiz OD, Clark SK, Hart AL. Systematic review with meta-analysis: the management of chronic refractory pouchitis with an evidence-based treatment algorithm.. Alimentary Pharmacology Therapeutics 2017;45(5):581–92. [PUBMED: 28008631]
63. Shepherd NA, Jass JR, Duval I, Moskowitz RL, Nicholls RJ, Morson BC. Restorative proctocolectomy with ileal reservoir: pathological and histochemical study of mucosal biopsy specimens. Journal of Clinical Pathology 1987;40(6): 601–7.
64. Shepherd NA, Hulten L, Tytgat GN, Nicholls RJ, Nasmyth DG, Hill MJ, et al. Pouchitis. International Journal of Colorectal Disease 1989;4(4):205–29.
65. Svaninger G, Nordgren S, Oresland T, Hulten L. Incidence and characteristics of pouchitis in the Kock continent ilesotomy and the pelvic pouch. Scandinavian Journal of Gastroenterology 1993;28(8):695–700.
66. Tremaine WJ, Sandborn WJ, Phillips SF, Pemberton JH, Carpenter HA. Short chain fatty acid (SCFA) enema therapy for treatment-resistant pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis (UC). Gastroenterology 1994;106:A784.
67. Tremaine WJ, Sandborn WJ, Kenan ML. Bismuth subsalicylate tablets for chronic antibiotic-resistant pouchitis. Gastroenterology 1998;114(1):A1101.
68. Tytgat GN, van Deventer SJ. Pouchitis. International Journal of Colorectal Disease 1988;3(4):226–8.
69. Zippi M, Cassieri C, Avallone EV, Pica R. Infliximab for the treatment of pouchitis. World Journal of Clinical Cases 2013;1(6):191–6.
70. Zuccaro G Jr, Fazio VW, Church JW, Lavery IC, Ruderman WB, Farmer RG. Pouch ileitis. Digestive Diseases and Sciences 1989;34(10):1505–10.
71. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database of Systematic Reviews 2010, Issue 6. DOI: 10.1002/14651858.CD001176.pub2
72. Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database of Systematic Reviews 2015, Issue 11. DOI: 10.1002/14651858.CD001176.pub3